ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

Salesforce (NYSE: CRM), the world’s #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliver life-changing medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology.

With Agentforce Life Sciences, Salesforce aims to help AstraZeneca unlock a new era of intelligent engagement — redefining customer relationships and accelerating business growth. The partnership will enable teams to focus on strategic customer outcomes and meaningful customer interactions.

Expanding its remit for AstraZeneca, Salesforce will support Agentforce 360 for Life Sciences as the global, end-to-end engagement solution for AstraZeneca, including:

  • Medical-Commercial Coordination: Consolidating healthcare professional (HCP) insights and surface context across teams.
  • Personalized Engagement: Scaling operations across key account, reimbursement, and field teams with next-best action recommendations. AstraZeneca will also orchestrate and automate digital campaigns across multiple channels based on customer preferences.
  • Model Context Protocol (MCP) Interoperability: Extending its composable architecture with Salesforce’s Agent Fabric, AstraZeneca will orchestrate internal and external agent actions across field engagement, commercial operations, and different brands and regions, allowing its care teams and AI agents to work seamlessly together.

“This partnership with AstraZeneca represents a clear step towards building intelligent, agentic customer engagement in the life sciences industry with their selection of Agentforce Life Sciences for Customer Engagement,” said Frank Defesche, SVP and GM of Life Sciences at Salesforce. “Together, we will empower AstraZeneca’s teams with the latest technology to deliver personalized engagement and accelerate the delivery of life-changing medicines to patients around the world.”

Learn more:

About Salesforce

Salesforce helps organizations of any size become Agentic Enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit www.salesforce.com for more information.

Any unreleased services or features referenced here are not currently available and may not be delivered on time or at all. Customers should make their purchase decisions based upon features that are currently available.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.80
+0.45 (0.20%)
AAPL  271.99
-1.68 (-0.61%)
AMD  214.79
+1.36 (0.64%)
BAC  55.97
+0.70 (1.26%)
GOOG  310.77
+2.16 (0.70%)
META  660.08
+1.31 (0.20%)
MSFT  486.18
+0.25 (0.05%)
NVDA  183.16
+2.17 (1.20%)
ORCL  197.24
+5.27 (2.74%)
TSLA  494.38
+13.18 (2.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.